Hims & Hers price target lowered to $25 from $28 at Deutsche Bank

Deutsche Bank analyst George Hill lowered the firm’s price target on Hims & Hers to $25 from $28 and keeps a Hold rating on the shares. The firm says Hims “navigated several major shifts” in its weight loss business since it launched compounding GLP-1. The company’s pressures “come on multiple fronts simultaneously,” including from the FDA compounding regulation, Novo Nordisk litigation, and the structural end of the semaglutide shortage window, the analyst tells investors in a research note.